PharmMedProm, 31 May 2023
Phs-Leksredstva will launch a new shop for the production of solid dosage forms. It will also start making gelatine capsules for medicinal products at its Kursk plant.
The Kursk region-based Russian enterprise Phs-Leksredstva will be the first in Russia to make medical gelatine. It will be used in the manufacture of drugs in soft gelatine capsules. The company's management has already reached a corresponding agreement with the region's administration. The agreement on trilateral cooperation for the coming year was signed during a business meeting between Roman Starovoit, Governor of the Kursk region, and Aleksandr Kosopletkin, General Director of Phs-Leksredstva JSC. The production of soft gelatine capsules for medicinal products is scheduled to launch in 2024.
“The facility uses raw materials made in the Kursk region for packaging. The company expects to start making drugs in gelatine capsules. The gelatine will be produced in our region,” said the head of the region.
In addition, the company plans to expand its solid dosage form manufacturing capacity and open a new shop for the production of tablets.
“At the end of June, we will launch a new shop that will make solid dosage forms. It will allow us to not only increase tablet output but also switch to a five-day week and eliminate night shifts,” said the director of Phs-Leksredstva JSC.
Phs-Leksredstva is part of Pharmstandard Group and is considered one of the five largest drug manufacturers in Russia. The enterprise actively participates in the Russian import substitution program, significantly contributing to the development of the Kursk region's economy, says the press service of the regional administration.
The plant features six workshops consisting of 26 production areas. With an output capacity of 600 mln packages per year, the plant manufactures almost 500 types of drugs, of which 20 were launched in 2022.
Pharmstandard Group has a total of five plants in Russia: in Kursk, Ufa, Tomsk, Vladimir, and Moscow regions. The manufacturer produces drugs for cardiovascular diseases, diabetes, growth hormone deficiency, gastroenterological, neurological, and infectious diseases, metabolic disorders, and cancer, among others.
| Back | Print out |
